Cargando…
Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: A multicenter comparison study
BACKGROUND: Recurrent bleeding is one of the major causes of morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). Antifibrinolytic therapy is known to reduce recurrent bleeding, however, its beneficial effect on outcome remains unclear. The effect of treatment with tra...
Autores principales: | Post, R., Germans, M. R., Boogaarts, H. D., Ferreira Dias Xavier, B., Van den Berg, R., Coert, B. A., Vandertop, W. P., Verbaan, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366882/ https://www.ncbi.nlm.nih.gov/pubmed/30730957 http://dx.doi.org/10.1371/journal.pone.0211868 |
Ejemplares similares
-
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial
por: Germans, Menno R, et al.
Publicado: (2013) -
Platelet transfusion in patients with aneurysmal subarachnoid hemorrhage is associated with poor clinical outcome
por: Post, R., et al.
Publicado: (2020) -
Aneurysm treatment within 6 h versus 6–24 h after rupture in patients with subarachnoid hemorrhage
por: Vergouwen, Mervyn DI, et al.
Publicado: (2023) -
Update of the ULtra-early TRranexamic Acid after Subarachnoid Hemorrhage (ULTRA) trial: statistical analysis plan
por: Post, René, et al.
Publicado: (2020) -
Prehemorrhage antiplatelet use in aneurysmal subarachnoid hemorrhage and impact on clinical outcome
por: Sebök, Martina, et al.
Publicado: (2021)